Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Return on Capital Employed (2016 - 2025)

Heron Therapeutics' Return on Capital Employed history spans 13 years, with the latest figure at 0.02% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 7.0% year-over-year to 0.02%; the TTM value through Dec 2025 reached 0.02%, up 7.0%, while the annual FY2025 figure was 0.02%, 7.0% up from the prior year.
  • Return on Capital Employed reached 0.02% in Q4 2025 per HRTX's latest filing, down from 0.01% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.01% in Q3 2025 to a low of 1.46% in Q2 2022.
  • Average Return on Capital Employed over 5 years is 0.66%, with a median of 0.8% recorded in 2021.
  • Peak YoY movement for Return on Capital Employed: plummeted -61bps in 2022, then soared 77bps in 2024.
  • A 5-year view of Return on Capital Employed shows it stood at 0.84% in 2021, then decreased by -16bps to 0.98% in 2022, then increased by 22bps to 0.76% in 2023, then surged by 89bps to 0.09% in 2024, then surged by 81bps to 0.02% in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Return on Capital Employed are 0.02% (Q4 2025), 0.01% (Q3 2025), and 0.05% (Q2 2025).